Please wait a minute...
Reviews in Cardiovascular Medicine  2021, Vol. 22 Issue (3): 585-595     DOI: 10.31083/j.rcm2203070
Special Issue: Drug-Coated balloons-The “leave nothing behind” strategy
Review Previous articles | Next articles
Progress on developing an effective below-the-knee drug-coated balloon
Rym El Khoury1, Marianne Brodmann2, Peter A. Schneider1, *()
1Division of Vascular and Endovascular Surgery, University of California, San Francisco, CA 94143, USA
2Division of Angiology, Medical University Graz, 8036 Graz, Austria
Download:  PDF(472KB)  ( 349 ) Full text   ( 39 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
Infrapopliteal atherosclerotic disease continues to present the greatest conundrum for effective endovascular therapies. To date, conventional angioplasty has been fraught with early restenosis and recoil in these complex, long, calcified, and occlusive lesions. The success of metallic drug-eluting stents in coronary arteries has not carried over to below-the-knee arteries. Initial promise in paclitaxel-coated balloons has not been demonstrated in large randomized clinical trials. Furthermore, the potential association between paclitaxel and mortality continues to generate tremendous controversy. The goal of this review article is to discuss the evolution and challenges of drug-coated balloon (DCB) science, present the clinical results of currently available tibial DCBs, and introduce new horizons in DCB technology.
Key words:  Drug-coated balloon      Device design      Below-the-knee      Infrapopliteal      Peripheral arterial disease     
Submitted:  02 August 2021      Revised:  18 August 2021      Accepted:  25 August 2021      Published:  24 September 2021     
*Corresponding Author(s):  Peter A. Schneider     E-mail:  peter.schneider@ucsf.edu

Cite this article: 

Rym El Khoury, Marianne Brodmann, Peter A. Schneider. Progress on developing an effective below-the-knee drug-coated balloon. Reviews in Cardiovascular Medicine, 2021, 22(3): 585-595.

URL: 

https://rcm.imrpress.com/EN/10.31083/j.rcm2203070     OR     https://rcm.imrpress.com/EN/Y2021/V22/I3/585

[1] Ibrahim Sidiqi, Patrick Alexander. Current Advances in Endovascular Therapy for Infrapopliteal Artery Disease[J]. Reviews in Cardiovascular Medicine, 2015, 16(1): 36-50.
[2] Victor Marinescu, Karolina K. Mirowska, Theodore Schreiber, Mahir Elder, Mircea Petrina. Insights Into Endovascular Revascularization in Limb Salvage Procedures: "Antegrade-Retrograde" Technique in Chronic Total Occlusion[J]. Reviews in Cardiovascular Medicine, 2011, 12(1): 42-47.
[3] Norman E. Lepor. Key Findings From the 2006 World Congress of Cardiology[J]. Reviews in Cardiovascular Medicine, 2007, 8(2): 90-100.
[4] Kanwar P. Singh, Manesh R. Patel, James P. Zidar, David E. Kandzari. Peripheral Arterial Disease: An Overview of Endovascular Therapies and Contemporary Treatment Strategies[J]. Reviews in Cardiovascular Medicine, 2006, 7(2): 55-68.
[5] Jeffrey T. Lu, Mark A. Creager. The Relationship of Cigarette Smoking to Peripheral Arterial Disease[J]. Reviews in Cardiovascular Medicine, 2004, 5(4): 189-193.
[6] . Best of the AHA Scientific Sessions 2003[J]. Reviews in Cardiovascular Medicine, 2004, 5(1): 26-52.
[7] Jeanne Doyle, Mark A. Creager. Pharmacotherapy and Behavioral Intervention for Peripheral Arterial Disease[J]. Reviews in Cardiovascular Medicine, 2003, 4(1): 18-24.
[8] . Best of the AHA Scientific Sessions 2002[J]. Reviews in Cardiovascular Medicine, 2003, 4(1): 25-46.
[9] Kenneth Ouriel. Comparison of Surgical and Thrombolytic Treatment of Peripheral Arterial Disease[J]. Reviews in Cardiovascular Medicine, 2002, 3(S2): 7-16.
[10] . Best of the AHA Scientific Sessions 2001[J]. Reviews in Cardiovascular Medicine, 2002, 3(1): 22-48.
[11] Joseph M. Garasic, Mark A. Creager. Percutaneous Interventions for Lower-Extremity Peripheral Atherosclerotic Disease[J]. Reviews in Cardiovascular Medicine, 2001, 2(3): 120-125.
No Suggested Reading articles found!